A Phase II, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Determine the Safety and Efficacy of a Topical Patch (AB001) Following Daily Administration for 2 Weeks in Patients With Chronic Low Back Pain
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2016
At a glance
- Drugs AB 001 (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Frontier Biotechnologies
- 22 Jun 2016 Primary endpoint has been met. (Change of Pain intensity on VAS on Day 15), as reported in a Frontier Biotechnologies media release.
- 22 Jun 2016 Results published in a Frontier Biotechnologies media release.
- 02 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History